Jideytro (zidesamtinib) approved in the US for previously treated ROS1-positive non-small cell lung cancer
RegulatoryapprovedJideytroPositive
AI Analysis
Summary
Jideytro (zidesamtinib), developed by GlaxoSmithKline, has received FDA approval in the US for the treatment of previously treated ROS1-positive non-small cell lung cancer.
Outcome Details
FDA approval in the US for previously treated ROS1-positive non-small cell lung cancer
Importance:8/10
Sentiment:
0.90
FDA approvaloncologylung cancerROS1-positivetargeted therapy
Related Companies
Read the original article
Published by yahoo_finance on July 22, 2026 5:58 PM